Company Description
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.
The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction.
In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention.
The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 370 |
| CEO | Bobak Azamian |
Contact Details
Address: 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 United States | |
| Phone | (949) 418-1801 |
| Website | tarsusrx.com |
Stock Details
| Ticker Symbol | TARS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001819790 |
| CUSIP Number | 87650L103 |
| ISIN Number | US87650L1035 |
| Employer ID | 81-4717861 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| Jeffrey S. Farrow CPA | Chief Financial Officer and Chief Strategy Officer |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer |
| Aziz Mottiwala M.B.A. | Chief Commercial Officer |
| Dr. Elizabeth Yeu M.D. | Chief Medical Officer |
| David Nakasone | Head of Investor Relations |
| Dr. Bryan Wahl J.D., M.D. | General Counsel and Corporate Secretary |
| Adrienne Kemp | Senior Director of Corporate Communications |
| Matthew Rossen M.B.A. | Vice President of Marketing |
| Scott Youmans | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 144 | Filing |
| Feb 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 23, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 144 | Filing |
| Dec 29, 2025 | 144 | Filing |
| Dec 16, 2025 | 144 | Filing |